CALL - SPRINTER OPEN END - AMGEN | Delayed Deutsche Boerse AG 10:47:16 2024-05-20 EDT | ||
| 9.57 EUR | +1.27% |
|
| Current month | +59.90% | ||
| 1 month | +85.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 9.57 | +1.27% |
| 24-05-17 | 9.45 | -1.05% |
| 24-05-16 | 9.55 | -3.54% |
| 24-05-15 | 9.9 | +10.00% |
| 24-05-14 | 9 | +1.35% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 10:47 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV16X3 |
| ISIN | DE000VV16X37 |
| Date issued | 2022-05-06 |
| Strike | 211.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.96 € |
|---|---|
| Lowest since issue | 1.32 € |
| Spread | 0.02 € |
| Spread % | 0.21% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.5
USD
Average target price
314.6
USD
Spread / Average Target
+0.70%
- Stock Market
- Certificates
- Certificat
